|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, NKG2D-DAP10 receptor complexes may activate NK and T cell responses against MICA-bearing tumors.
|
10426994 |
1999 |
|
KLRC4-KLRK1
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of the NKG2D ligands is low or absent on normal, adult tissues; however, they are constitutively expressed on some tumors and upregulated by retinoic acid.
|
10894171 |
2000 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
Notably, NK cell clones expressing low surface densities of NCR (NCR(dull)) could lyse these tumors in an exclusively NKG2D-dependent fashion.
|
11298332 |
2001 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
The combination strategy demonstrated a clear synergistic interaction between cisplatin and IL-2, and NKG2D-based cytotoxicity manifested by increased tumor specific lysis from CTLs and natural killer cells.
|
12124336 |
2002 |
|
KLRC4-KLRK1
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of NKG2D is reduced markedly on large numbers of tumour-infiltrating and matched peripheral blood T cells from individuals with cancer.
|
12384702 |
2002 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
MICA expression is up-regulated upon cellular stress and its expression is correlated to infiltration of human NKG2D-bearing T cells into the tumors.
|
12894536 |
2003 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent advances in our understanding of NK cell function are due to the identification of activating NK cell receptors, such as Ly49H and NKG2D, for specific viral and tumor ligands (m157 and Rae1, respectively).
|
14688463 |
2004 |
|
KLRC4-KLRK1
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This soluble form of MIC engages cells expressing NKG2D, rendering them inactive, and impairs tumour cytolysis.
|
15182323 |
2004 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
Paradoxically, studies suggest that tumors may evade MIC-NKG2D-mediated immunity by MIC shedding-induced impairment of effector cell function.
|
15314693 |
2004 |
|
KLRC4-KLRK1
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Here, the expression of NKG2D ligands was investigated in human primary NB tumors and cell lines because scanty information is available on this issue.
|
15548365 |
2005 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
Blocking of these ligands using NKG2D tetramers abrogated tumor killing in vitro and in vivo.
|
15769894 |
2005 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we demonstrate that DNA-based vaccines, encoding syngeneic or allogeneic NKG2D ligands together with tumor antigens such as survivin or carcinoembryonic antigen, markedly activate both innate and adaptive antitumor immunity.
|
16040807 |
2005 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
This review summarizes the biological properties of NKG2D and its ligands and discusses the interactions and regulation of these molecules with emphasis of their significance in microbial infections, tumor immunology, and autoimmune disease.
|
16329186 |
2006 |
|
KLRC4-KLRK1
|
0.100 |
AlteredExpression
|
group |
BEFREE |
IFN-dependent down-regulation of the NKG2D ligand H60 on tumors.
|
16393975 |
2006 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
It also unveiled a frequent enhancing effect of NKG2D on tumor killing by Vgamma9Vdelta2 T cells.
|
17056540 |
2006 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, our data provide strong evidence for an immune escape mechanism of tumors via alternative splicing of ULBP RNA to generate a free soluble ULBP protein, RAET1E2, that may impair NKG2D-mediated NK cell cytotoxicity to tumors.
|
17470428 |
2007 |
|
KLRC4-KLRK1
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Comparison of level of NKG2D ligands between normal and tumor tissue using multiplex RT-PCR.
|
17661204 |
2007 |
|
KLRC4-KLRK1
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The heat shock protein HSP70 promotes mouse NK cell activity against tumors that express inducible NKG2D ligands.
|
17911639 |
2007 |
|
KLRC4-KLRK1
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Thus, it is essential to regulate the expression of NKG2D ligands in order to ensure effective tumor immunosurveillance and the elimination of pathogen-infected cells.
|
18422748 |
2008 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
Current evidence suggests that established tumors subvert NKG2D-mediated tumor immunosurveillance by releasing NKG2D ligands (NKG2DL).
|
18508446 |
2008 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
Strategies to amplify NKG2D-mediated antitumor responses and counteract tumor immune escape mechanisms will be discussed.
|
18836475 |
2008 |
|
KLRC4-KLRK1
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Whereas MICA expressed on the cell surface stimulates the immunoreceptor natural killer group 2, member D (NKG2D), the secreted form down-regulates NKG2D activity, thus allowing the tumor to escape immunosurveillance by NKG2D-expressing cells.
|
18951065 |
2009 |
|
KLRC4-KLRK1
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent studies in mice demonstrated that NKG2D mediates tumor immune surveillance, suggesting that antitumor immunity in humans could be enhanced by therapeutic manipulation of NKG2D ligand (NKG2DL) expression.
|
19089914 |
2009 |
|
KLRC4-KLRK1
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Correspondingly, expression of NKG2D ligands on target cells is a requirement for effective tumor immunosurveillance and the elimination of pathogen-infected cells.
|
19139882 |
2009 |
|
KLRC4-KLRK1
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expanded NK cells had increased TRAIL, FasL and NKG2D expression and significantly higher cytotoxicity against bortezomib-treated tumors compared with resting NK cells.
|
19308771 |
2009 |